key: cord-0873412-v8mctp0u
authors: Prendecki, Maria; Clarke, Candice; Brown, Jonathan; Cox, Alison; Gleeson, Sarah; Guckian, Mary; Randell, Paul; Pria, Alessia Dalla; Lightstone, Liz; Xu, Xiao-Ning; Barclay, Wendy; McAdoo, Stephen P; Kelleher, Peter; Willicombe, Michelle
title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
date: 2021-02-25
journal: Lancet
DOI: 10.1016/s0140-6736(21)00502-x
sha: 2bd4127d7c6b3956d16c76f938abe922dc580da2
doc_id: 873412
cord_uid: v8mctp0u

nan

of SARS-CoV-2 infection, it would be unwise to let the virus circulate in children, with consequent risk to their families. Reopening fully in the setting of high community transmission without appropriate safeguards risks depriving many children of education and social interaction again, worsening existing inequalities. By contributing to high community transmission, it also provides fertile ground for virus evolution and new variants.

Multi-layered mitigations can substantially reduce the risk of transmission within schools and into households. 13 In the panel we summarise a set of recommendations that are in line with guidelines from the US Centers for Disease Control and Prevention (CDC) and practised in many countries to reduce the risk of transmission in schools and mitigate the impact of COVID-19 on children and families. A detailed set of recommendations and an infographic are provided in the appendix. Making schools safer goes hand in hand with reducing community transmission and is essential to allow schools to safely reopen and remain open. NAA Although baseline ELISpot data were not available for these five participants, a cohort of 30 unvaccinated, infection-naive participants did not demonstrate reactivity to these peptide pools. 51 participants had negative baseline serology and cellular responses post-vaccine limited to spike infection 5 weeks after one dose of vaccine; notably, their anti-S titre postvaccination was 61·8 AU/mL. In keeping with published reports of other vaccines, serological response to BNT162b2 inversely correlates with age. 14 We found median anti-S titres post-vaccination in the infectionnaive cohort to be lower than those seen 2-8 weeks after natural infection alone, and this difference was particularly striking in those older than 50 years. Two participants did not seroconvert, and eight participants generated antibody titres less than 250 AU/mL, which might not be sufficient for any virus neutralisation based on correlation of virus neutralisation and anti-S titre in our study. All ten of these individuals were older than 50 years. In a setting where prioritisation of groups of HCWs for second vaccination might be necessary, consideration must be given to protocolised vaccination of infection-naive individuals or those over the age of 50 (who are at increased risk of both severe COVID-19 and minimal vaccine response). These results also highlight the need for continuing rigorous use of personal protective equipment after vaccination to prevent both infection and asymptomatic spread of disease.

MP, CC, PK, and MW contributed equally. PK and MW have received support to use the T-SPOT Discovery SARS-CoV-2 from Oxford Immunotec. X-NX and PK are supported by the Department for International Development and the Wellcome Trust. MP is supported by the National Institute for Health Research (NIHR). All other authors declare no competing interests. We thank the HCWs who participated in this study. We also thank Graham Pickard and Donald Mokreri for help with the spike protein antibody assay. We acknowledge support from the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. ; figure E, F), and 24 (50%) of 48 participants generated T-cell responses that could be con sidered negative (<40 SFU/10⁶ PBMC). Unlike humoral responses, there was no correlation between age and degree of T-cell response.

In summary, we show that individuals with previous SARS-CoV-2 infection generate strong humoral and cellular responses to one dose of BNT162b2 vaccine, with evidence of high titres of in-vitro live virus neutralisation. In contrast, most individuals who are infection-naive generate both weak T-cell responses and low titres of neutralising antibodies.

Existing studies predicting risk of re-infection based on neutralising antibody titres, or longevity of immunological responses, are highly heterogeneous. [9] [10] [11] [12] [13] Evidence for the longevity and protective effect of T-cell responses is particularly limited. In particular, peptide pool selection might affect T-cell responses, meaning results cannot be compared between studies. We use S1 and S2 peptide pools, rather than peptides spanning the whole spike glycoprotein, which might underestimate the true magnitude of T-cell responses. Despite the difficulty of extrapolating immunological data to clinical protection, our findings raise important issues that warrant consideration when determining optimal use of vaccine supplies. Firstly, those with serological evidence of previous disease at baseline mount robust antibody and T-cell responses after a single dose of vaccine. Conversely, some infection-naive individuals mount very little demonstrable response to single-dose vaccination, which might not provide sufficient immunity to protect from clinical disease or viral shedding, and might not persist for a 12-week delay until second vaccine is administered. One infection-naive individual included in our study developed symptomatic, PCR-proven previously infected groups (figure A). Infection-naive individuals showed an inverse correlation between postvaccination anti-S titre and age (figure B), with individuals older than 50 years generating a significantly weaker serological response than those younger than 50 years (median 230·1 AU/mL vs 888·9 AU/mL, p<0·0001; figure A) . This correlation was not seen in the group with previous natural infection ( figure B) .

Anti-S titre is reported to correlate with in-vitro virus neutralisation. We therefore used a subset of samples for live SARS-CoV-2 virus (SARS-CoV-2/ England/IC19/2020) neutralisation assays on Vero cells. 8 Eight paired sera (n=4 infection-naive, n=4 previous natural infection) and a further 15 post-vaccination samples were included (n=12 infection-naive, n=3 previous natural infection). In individuals with previous exposure, vaccine induced very strong neutralising antibody titres even in those without detectable or very low virus neutralisation titres (NT) at baseline (median NT that achieved 50% neutralisation [NT 50 ] 1/1635, range 1/1123·1 to beyond the 1/2560 upper limit; figure C, D). In infectionnaive individuals, vaccination induced detectable neutralising antibodies in 15 of 16 sera, but titres were all lower than for previously infected individuals (median NT 50 1/29·50, range from below lower limit of detection to 1/68; figure C, D).

We next assessed post-vaccination T-cell responses using the T-SPOT Discovery SARS-CoV-2 (Oxford Immunotec, Oxford, UK), which includes a panel of five SARS-CoV-2 peptide pools. Post-vaccination, participants with evidence of previous SARS-CoV-2 infection at baseline (n=21) mounted very strong T-cell responses to spike peptides (median 400 SFU/10⁶ PBMC [IQR 287-544]; figure E, F). In the infection-naive group, post-vaccination T-cell responses to spike peptides were significantly weaker than in individuals with previous infection Learning from these consequences, a more constructive perspective could view the anti-vax movement as a religious phenomenon, involving a whole spectrum of ideas, and focus on the essential need to understand the beliefs that are involved to avoid further marginalisation. Hence, implying that anti-vaxxers are beyond the reach of community engagement activities could result in increased anti-vax activities. We suggest a more inclusive approach, where the same inquisitive dialogue and contextual understanding that was suggested for vaccine hesitancy should be extended to members of the anti-vax movement. 

Rochelle Burgess and colleagues 1 eloquently described participatory community engagement as essential for successful COVID-19 vaccination, which involves appreciating the heterogeneous public and working with communities and their leaders to enable bottom-up approaches. They suggested that COVID-19 has drawn attention to the structural violence that is embedded within society, with the pandemic furthering the marginalisation of historically oppressed and excluded groups. Burgess and colleagues 1 drew attention to how people who might have suffered disproportionate economic and health consequences from COVID-19 are now being asked "to trust the same structures" 1 that failed to provide adequate resources and social protection during the pandemic. Failure to address these contextual dimensions can worsen mistrust, damaging vaccine uptake. However, Burgess and colleagues make a distinction between "people wholly opposed to vaccinations (anti-vaxxers) and…vaccine hesitancy", 1 and imply participatory community engagement as a means to engage only people with vaccine hesitancy. Lessons from studying cults (which are less pejoratively called new religious movements, describing movements that emerged in the late 20th century) can inform approaches to the antivax movement. A cult has come to mean a non-conforming ideology, or a religion that is disliked, with beliefs that are unacceptable to mainstream society. Just as cults are grouped together as sinister, bad, or wrong, the discourse surrounding anti-vaxxers in both academic and popular circles can be dismissive and derogatory. The pejorative label and negative attitudes towards cults promote an us-andthem viewpoint, creating martyrs 2,3 and extending the length of time that members hold the new beliefs, thus encouraging further involvement in the movement and radicalisation. 4 

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

Covid-19: medical community split over vaccine interval policy as WHO recommends six weeks

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: a prospective cohort study in keyworkers

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Factors that influence the immune response to vaccination

The attention to health systems in the headline of Ann Usher's World Report 1 about the Access to COVID-19 Tools Accelerator (ACT-A) is most welcome. However, we were disappointed that the World Report focused on medical oxygen and personal protective equipment (PPE), interventions that, although important, are better described as components of clinical Indranil Mukherjee/Getty Images